Contraception
Volume 74, Issue 6 , Pages 446-450 , December 2006

Effect of a combination of ethinylestradiol 30 μg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception

  • Lavínia E. Borges

      Affiliations

    • Laboratório de Reprodução Humana do Hospital das Clínicas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil
    • ,
  • Rosires P. Andrade

      Affiliations

    • Centro de Estudos e Pesquisas em Reprodução Humana e Fertilização Assistida de Curitiba, Curitiba, Brazil
    • ,
  • José M. Aldrighi

      Affiliations

    • Departamento de Ginecologia e Obstetrícia da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
    • ,
  • Cristina Guazelli

      Affiliations

    • Departamento de Obstetrícia da Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil
    • ,
  • Marta Edna H.D. Yazlle

      Affiliations

    • Departamento de Ginecologia e Obstetrícia do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, São Paulo, Brazil
    • ,
  • Carlos F. Isaia

      Affiliations

    • Centro de Medicina Reprodutiva Dr. Carlos Isaia Filho, Porto Alegre, Brazil
    • ,
  • Alvaro Petracco

      Affiliations

    • Departamento de Ginecologia e Obstetrícia da Pontifícia Universidade Católica do Rio Grande do Sul, Rio Grande do Sul, Brazil
    • ,
  • Fabio C. Peixoto

      Affiliations

    • Laboratório de Reprodução Humana do Hospital das Clínicas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil
    • ,
  • Aroldo F. Camargos

      Affiliations

    • Laboratório de Reprodução Humana do Hospital das Clínicas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil
    • Corresponding Author InformationCorresponding author. Rua dos Otoni 881 sala 403, cep-30150270, Belo Horizonte, Brazil.

Received 3 August 2005 ,Revised 30 October 2005 ,Accepted 30 October 2005.

References 

  1. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin™, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105–111
  2. Neuman F. Chemische konstituition und pharmakologische wirkung. In:  Junkmann K editors. Handbook of experimental pharmacology, Vol 23, Part 1: Die Gestagene. Berlin: Spring Verlag; 1968;p. 680–1025
  3. Oelkers W, Schöneshöfer M, Blumel A. Effects of progesterone and four synthetic progestogen on sodium balance and the renin–aldosterone system in man. J Clin Endocrinol Metab. 1974;39:882–890
  4. Oelkers W, Berger V, Bolik A, et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion and the renin–aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73:837–842
  5. Muhn P, Fuhrmann V, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311–335
  6. Dickerson V. Quality of life issues: potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. J Reprod Med. 2002;47:985–993
  7. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  8. Fuhrmann V, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54:243–251
  9. Sundsfjord JÁ, Aakavaag A. Plasma angiotensin II and aldosterone excretion during the menstrual cycle. Acta Endocrinol. 1970;64:452–458
  10. Oelkers WKH. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids. 1996;61:166–171
  11. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann Contracept. 1995;51:99–110
  12. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Drug Res. 1985;35:459–471
  13. Rosenberg M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–582
  14. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive technology. New York: Irvington Publishers; 1994;
  15. Englander-Golden P, Whitmore MR, Dienstbier RA. Menstrual cycle as a focus of study and self-reports of moods and behaviour. Motiv Emot. 1978;2:75–86
  16. Magos AL, Studd JWW. The premenstrual syndrome. In:  Magos AL,  Studd JWW editor. Progress in obstetrics and gynecology. vol. 4:Edinburg: Churchill Livingstone; 1984;p. 334–350
  17. Mortola JF, Girton L, Beck L, Yen SSC. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol. 1990;76:302–307

PII: S0010-7824(05)00435-X

doi: 10.1016/j.contraception.2005.10.016

Contraception
Volume 74, Issue 6 , Pages 446-450 , December 2006

Article Tools

* Image Usage & Resolution